[Music] Good afternoon everyone. I'm and you or you can call me Kira and I come from the Mongol ethnic group in the hotel. Today I want to share with you a story about how three languages Mongolia, Chinese and English have shaped my identity, my life and my worldview.Growing up, I never thought of language as merely true to for communication. For me, each language is a doorway to a different world, a unique way of thinking and a distinct way of being. These three languages does not only define my cultural e ...

[Music] Well, hi everyone. I am Pal. As you heard, I'm a 21-year-old Zu change maker.What I don't tell often is that I'm an introvert turn speaker. So, when I stand on the stage, I'm nervous. And yes, I'm also a content creator.Do we recognize what this is. Do we recognize this. Everyone in the room from the nods and the smiles.Yes, this is an hourglass and I know we've been talking about the hourglass through different experiences and conversations and examples throughout the day, but we will continue to d ...

Nvidia (NVDA 2.05%) remains one of the best artificial intelligence (AI) stocks on the market. But with the chipmaker now trading at a price-to-sales multiple of 26.4, many investors may wonder if shares have gotten too expensive to buy. Don't be fooled: Nvidia stock is still reasonably priced.Nvidia stock isn't as expensive as it seemsNvidia designs graphics processing units (GPUs) that provide the processing power required to support modern AI and machine-learning software. The company's gross margins are ...

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics platform [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to create a new entity named Decoy Therapeutics, with Decoy investors expected to own approximately 92.4% of the merged company [2][10] - The combined company will focus on developing peptide conjugate therapeutics for unmet medical needs in respiratory infectious diseases and gastroenterology oncology [3][8] Research Insights - Recent animal studies published highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies provide insights into the role of KDM1A in regulating neural stem cell fate and its implications in oral squamous cell carcinoma progression [5][6] Future Plans - Decoy Therapeutics plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6][7] - The ongoing clinical trial at MDACC is expected to report data on patients with MDS and CMML who have previously failed or relapsed after hypomethylating agent therapy [7][9]

Core Insights - Salarius Pharmaceuticals is advancing its Phase 1/2 clinical study of seclidemstat for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) with updates expected later this year [1][2] - The company is progressing with its planned merger with Decoy Therapeutics, which is anticipated to create value through Decoy's innovative peptide conjugate therapeutics [2][3] Company Developments - Salarius' seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor being evaluated at MD Anderson Cancer Center [1][9] - The merger with Decoy Therapeutics is set to combine Salarius' drug candidates with Decoy's IMPACT™ platform, which focuses on developing therapeutics for respiratory viruses and cancer [3][10] - The combined company will be led by Decoy's executive team, including CEO Frederick "Rick" Pierce and CSO Barbara Hibner [4] Research Insights - Two recent animal studies highlight the importance of inhibiting LSD1 expression, supporting the potential of SP-2577 in cancer treatment [2][5] - The studies published in peer-reviewed journals provide insights into the role of KDM1A in regulating neural stem cells and oral squamous cell carcinoma progression [5] Future Plans - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, towards an Investigational New Drug (IND) application with the FDA within the next 12 months [6] - The ongoing clinical trial at MDACC may yield data on MDS and CMML patients who have previously failed or relapsed after hypomethylating agent therapy [7]

Core Insights - The article highlights the emergence of AI products developed by Chinese teams, particularly focusing on Pokee AI, which has successfully raised $12 million in seed funding aimed at automating enterprise workflows [1][12]. Group 1: Company Overview - Pokee AI is led by Bill Zhu, a former head of the reinforcement learning group at Meta, and aims to automate online workflows for users by integrating AI functionalities into existing tools and services [1][11]. - The funding round was led by Point72 Ventures, with participation from Qualcomm, Samsung, and other notable investors, indicating strong market interest and confidence in the product [1][12]. Group 2: Product Features - Pokee AI integrates AI capabilities into various platforms such as Google Workspace, Meta platforms, LinkedIn, and more, allowing users to automate tasks without switching between different tools [2][3]. - The product targets three core scenarios: AI + Productivity, AI + Social Media, and AI + Research & Engineering, addressing common pain points in workflow automation [9]. Group 3: Technology and Approach - Unlike many AI agents that rely on large language models (LLMs), Pokee AI utilizes reinforcement learning (RL) to tackle the execution of complex tasks, which is seen as a significant advantage [6][11]. - The RL approach allows the AI to learn from interactions with the environment, improving its decision-making and execution capabilities, achieving over 97% accuracy in selecting from thousands of tools [11]. Group 4: Market Context - The article notes a growing trend among Chinese AI teams to create innovative solutions for enterprise-level automation, with other products also securing significant funding and market traction [12][15]. - The focus on automating repetitive tasks and enhancing productivity reflects a broader industry shift towards integrating AI into everyday business processes [8][12].

French lessons offered as ferry visitors surge https://t.co/LWTWtzlP97 ...

Core Viewpoint - Victory Square Technologies Inc. reported solid financial results for Q1 2025 and emphasized its strategic focus on the digital health and wellness sectors, identifying significant growth opportunities in a fragmented healthcare market [4][11]. Financial Highlights - Adjusted Revenue for Q1 2025 was $6.528 million, while GAAP Revenue stood at $4.540 million. The Cost of Goods Sold (COGS) was $3.036 million, resulting in a Gross Margin of $1.504 million. As of March 31, 2025, the company had Cash & Marketable Securities amounting to $9.698 million [7]. Business Focus Areas - The company aims to scale its holdings in the digital health sector, particularly through its flagship portfolio company, Hydreight Technologies, which provides a compliant platform for healthcare services across the U.S. [4][8]. - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early trials showing promising results in insulin uptake [8][14]. - Pawsible Ventures is focused on pet wellness and telehealth, leveraging trends in human healthcare, with the global pet care market projected to reach $368 billion by 2030 [10][14]. Portfolio Management - Victory Square actively manages its portfolio, having sold certain AI fintech solutions for approximately $880,000 in equity consideration in Q1 2025. This follows a previous sale of BlockX for about $1.7 million in listed shares [11][15]. Industry Context - The U.S. healthcare spending exceeds $4.5 trillion annually and is projected to reach $7 trillion by 2031, highlighting the sector's fragmentation and potential for value creation [4]. - The global diabetes therapeutics market is expected to reach $118 billion by 2032, with over 500 million people currently living with diabetes [14]. Upcoming Events - Victory Square will host an Investor Webinar on July 17, 2025, to provide updates and address investor questions [12]. Leadership and Strategy - The leadership team at Insu Therapeutics includes experienced professionals from academia and the pharmaceutical industry, indicating a strong foundation for advancing its clinical milestones [14]. - The company’s business model focuses on buying, building, and investing in early-stage tech companies, with a commitment to supporting their growth for up to 48 months [17].

Feasibility of Understanding Large Language Models - The field of mechanistic interpretability has a significant advantage due to perfect access to neurons, parameters, weights, and attention patterns in neural networks [1] - Understanding large language models is deeply necessary and critical for the future [2] - Establishing a norm to explain a percentage of the network by reconstructing it and extracting its concepts and features is crucial [2] Approaches to Understanding - Progress can be made by trying to understand all aspects of the network [2] - A baseline rudimentary understanding can be used to improve and understand more of the network [3]

Storytelling Fundamentals - Storytelling transforms simple messages into unforgettable experiences [4] - Visual storytelling combines words with visuals to create lasting memories [6] - Storytelling is an art that shapes learning, understanding, and memory [5] - Storytelling is about expressions, finding a medium that connects deeply with the audience [8] Application of Storytelling - Storytelling can be used to teach life lessons effectively [3] - Visual storytelling enhances learning by turning stories into animated visuals [5] - Art can serve as a form of storytelling, expressing emotions and ideas without words [7] - Storytelling is central to content creation and art direction [8] Impact and Purpose - Stories help people remember information and make them feel [9] - Storytelling connects, creates, and inspires [9]